Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.
Nelson
Mark R
MR
D001315:Australia; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005194:Family Practice / Q000639:trends*; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians'; D011720:Pyrazoles; D013449:Sulfonamides / Q000627:therapeutic use*; D013450:Sulfones
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib